Daily Archives: September 18, 2020

Imperial Capital Expands Emerging Markets Sales with the Hiring of Erik Hammes

LOS ANGELES, Sept. 18, 2020 (GLOBE NEWSWIRE) — Imperial Capital, LLC (“Imperial Capital”), announced today the continued growth of its dedicated Emerging Markets Sales and Trading Group with the hiring of senior sales professional, Erik Hammes.  Erik joins Imperial Capital in Stamford, CT where the Company has been adding key credit sales and trading talent over the past year.  Erik will report to James Kenney and Matt Clinton who joined Imperial Capital in November 2019 to co-head its Global Emerging Markets Sales & Trading Group.

“We are building an incredibly strong credit sales & trading team with years of experience across the asset classes and Erik joining us will allow our team to further provide our clients with emerging markets trading ideas,” said Tim Sullivan, President of Imperial Capital, LLC.

Erik Hammes joins Imperial as a Managing Director with over 23 years of credit sales and trading experience.  Prior to joining Imperial Capital, Mr. Hammes was a Director, Emerging Markets Credit Trader with Stifel.  Prior to this, he was with JPMorgan for 15 years, most recently as an Executive Director, Emerging Markets Credit Trader.  Mr. Hammes began his career in High Grade Trading with Bear Stearns.  Mr. Hammes earned an MBA from NYU and a BA from Georgetown University.

“Having worked with Erik in the past, I am very glad to have him on the team.  Adding quality hires in Emerging Markets is a key part of our growth strategy,” said James Kenny, Global Co-Head of Emerging Markets Sales & Trading.

About Imperial Capital, LLC

Imperial Capital, LLC is a full-service investment bank offering a uniquely integrated platform of comprehensive services to institutional investors and middle market companies. We offer sophisticated sales and trading services to institutional investors and a wide range of investment banking advisory, capital markets and restructuring services to middle market corporate clients. Paired with our proprietary research and sales & trading desk analysis, we provide investment analysis across an issuer’s capital structure, including bank loans, debt securities, the hybrid/bank capital marketplace (through our ELP Framework), post-reorganization equities, special situations claims and listed and unlisted equities. Our comprehensive and integrated service platform, expertise across the global capital structure, and deep industry sector knowledge enable us to provide clients with research driven ideas, superior advisory services, and trade execution. We are quick to identify opportunities under any market conditions and we have a proven track record of offering creative, proprietary solutions to our clients. Imperial Capital, LLC has three principal businesses: Investment Banking, Institutional Sales & Trading and Institutional Research. More information about Imperial Capital, LLC can be found at www.imperialcapital.com.

For more information regarding Imperial Capital, please contact:
Mark Martis
+1 310 246 3674
mmartis@imperialcapital.com

About Imperial Capital (International), LLP

Imperial Capital International, founded in 2011, is an affiliate of Imperial Capital, LLC with an office in central London.  Complementing Imperial Capital’s existing corporate credit sales and trading franchise, Imperial Capital International expanded the Imperial Capital franchise into the EEA.  The company focuses on the entire credit spectrum and takes a full capital structure research approach to supplement sales and trading services to its European institutional clients.

For more information regarding Imperial Capital (International), LLP, please contact:
Emma McClintock
+ 44 (0) 207 650 5429
emcclintock@imperialcapital.com

Radient Conducts Strategic Review of Operations and Announces Management Changes

EDMONTON, Alberta, Sept. 18, 2020 (GLOBE NEWSWIRE) — Radient Technologies Inc. (“Radient” or the “Company”) (TSX-V:RTI; OTCQX:RDDTF), a manufacturer of high quality cannabinoid-based formulations and products, announces its Board of Directors (the “Board”) is conducting a strategic review of the Company’s operations targeting a path to positive cash flow by evaluating costs and under utilized assets.  Radient will build on its recent successes in launching white label products and increasing its distribution to additional provinces. The review will address items that are strategic to the Company’s operations and includes management changes being announced today.

Today, the Board named Jan Petzel as Interim President and Chief Executive Officer, effective immediately. Mr Petzel has been a Director of the Radient since 2016 and has a comprehensive understanding of the Company, and a pragmatic view of the priorities that need to be addressed. Jan was a Managing Director in the Merchant Banking Division of Goldman Sachs, ultimately responsible for private credit in Germany and Scandinavia. While at Goldman Sachs, Mr. Petzel served on the board of several successful companies including Cognis GmbH, a worldwide supplier of specialty chemicals and nutritional ingredients, up to its sale to BASF for €3.1bn in 2010. He holds an MBA from Harvard Business School, a Master of Engineering from the Swiss Federal Institute of Technology and was a Visiting Scholar at the Massachusetts Institute of Technology.

Denis Taschuk will step down as President & Chief Executive Officer and Director of the Company, effectively immediately, for family reasons. He will continue as advisor to the Board to facilitate the transition to a new Chief Executive Officer. Denis has been instrumental in leading Radient to become a significant company in the cannabis industry, and the Board wishes to thank Denis for his contribution and tireless efforts over the last 10 years.

Mike Cabigon will step down as Chief Operating Officer and Director of the Company, effective immediately, to pursue other interests. Mike was instrumental in the Company’s pivot into the cannabis industry in 2016, and the Board thanks him for all his contribution over the years and wishes him well in his future endeavors.

About Radient

Radient Technologies is a commercial manufacturer of high-quality cannabinoid-based formulations, ingredients, and products. Utilizing a proprietary extraction and downstream processing platform that recovers up to 99% of cannabinoids from the cannabis plant, Radient develops specialty products and ingredients that contain a broad range of cannabinoid and terpene profiles while meeting the highest standards of quality and safety. Please visit www.radientinc.com for more information.

SOURCE: Radient Technologies Inc.

For further information please contact:
Radient – Investor Relations, ir@radientinc.com

Forward Looking Information:

This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. Forward-looking information includes, without limitation, statements regarding the growth of the Company’s business operations; the impact to the Company resulting from the review of operations and management changes, the Company’s ability to grow its business in the cannabis sector and the Company’s future plans. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved”. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Radient, as the case may be, to be materially different from those expressed or implied by such forward-looking information. Although Radient has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. Radient does not undertake to update any forward-looking information, except in accordance with applicable securities laws.

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

PRA Health Sciences and Deep Lens announce strategic relationship to accelerate patient recruitment for precision cancer trials

The two companies bring together cloud-based mobile technologies to improve the identification, screening and matching of patients to precision-based clinical oncology trials

RALEIGH, N.C. and COLUMBUS, Ohio, Sept. 18, 2020 (GLOBE NEWSWIRE) — PRA Health Sciences, Inc. (NASDAQ: PRAH) and Deep Lens, Inc., announced today a new strategic relationship to accelerate patient access and recruitment for oncology clinical trials. The relationship brings together best-in-class technologies that improve the identification, screening, and matching of cancer patients to precision-based clinical oncology trials on a global basis, with the combined solution being deployed to Microsoft Azure.

Deep Lens’ award-winning VIPERTM patient screening platform is a breakthrough technology deployed by cancer centers, integrated delivery networks (IDNs), and community oncology networks to identify and match oncology patients to life saving clinical trials who would have otherwise fallen through the cracks and missed the opportunity to enroll. The differentiated technology and services model allows Deep Lens to deploy its software at cancer centers and site networks on a global basis, free of charge, to better give patients access to the therapies they need and deserve – while providing significant value by accelerating study timelines and bringing game-changing therapies to market sooner.

“More than 14,000 oncology trials are currently recruiting patients, but estimates are that only three to five percent of eligible patients actually participate,” said Kent Thoelke, Chief Scientific Officer at PRA Health Sciences. “The challenges facing clinical trial recruitment are multifaceted, and sponsors have been unable to determine where specific patients are in order to match them to studies — that is about to change. Using Deep Lens’ VIPER technology, the patient identification process will be streamlined by instantly analyzing data within electronic health records, pathology systems and genomic profiles to enable matching of cancer patients with suitable clinical trials.”

The combined effort between PRA and Deep Lens brings a critical advancement to clinical trial matching to more efficiently connect eligible patients with potential clinical trials by leveraging artificial intelligence (AI) and machine learning via the VIPER platform.

How the VIPER Integration Works

VIPER enables cancer care teams, clinical trial sponsors and trial coordinators to immediately and automatically match patients based on the genetic profile of their cancers to the best precision therapies and oncology clinical trials.

VIPER is a HIPAA-compliant public cloud service that accesses data “behind the firewall” at participating sites and automatically ingests data from pathology systems at the time of diagnosis, and from electronic medical records and genetic test results from top genetic testing labs globally. VIPER acts as an AI-driven screening platform for research coordinators and care teams, while the de-identified data helps sponsors identify where in the process patients are being identified, where they may be disqualified and why they may or may not have enrolled in a trial once qualified. Currently, there is no workflow solution on the market that captures granular data about patients in their care continuum.

Once patients have been qualified for trials, the VIPER system will refer those patients to PRA’s industry leading Mobile Health Platform, also deployed on Azure, to provide an end-to-end patient-centric screening and trial management experience for providers globally.

The combination of VIPER’s artificial intelligence solution, workflow design, communication optimization and the research coordination services provides sponsors and research sites the best opportunity to connect the right patient, to the right trial, at the right time – it’s realization of personalized medicine.

“This will really move the needle in cancer research, and it will allow community oncology networks to compete with their much larger competitors at academic medical centers and comprehensive cancer centers,” Thoelke said. “With Microsoft Azure behind PRA and Deep Lens, we believe this relationship could create a game-changing model in cancer research, not only for patient screening but for the development of just-in-time networks and other new business models.”

“Deep Lens has grown dramatically with unique cloud technology and a business model that takes risk out of its deployment, and it has taken the vision of PRA to see the potential for a truly unique solution to come to market,” said Simon Arkell, Co-founder and President at Deep Lens. “With a global, industry-leading partner like PRA collaborating with Microsoft, we expect to exponentially grow our global footprint while dramatically increasing the success rates in oncology research. In turn, this will allow trial sponsors full visibility into the patient screening process so they can get their treatments to market much faster. Together, we will continue our mission to find the right patients for the right trials at the right time.”

About PRA Health Sciences

PRA Health Sciences is one of the world’s leading global contract research organizations by revenue, providing outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries. PRA’s global clinical development platform includes more than 75 offices across North America, Europe, Asia, Latin America, South Africa, Australia and the Middle East and more than 17,500 employees worldwide. Since 2000, PRA has participated in approximately 4,000 clinical trials worldwide. In addition, PRA has participated in the pivotal or supportive trials that led to U.S. Food and Drug Administration or international regulatory approval of more than 95 drugs. To learn more about PRA, please visit www.prahs.com.

INVESTOR INQUIRIES: InvestorRelations@prahs.com

MEDIA INQUIRIES: Laurie Hurst, Sr. Director, Communications and Public Relations
hurstlaurie@prahs.com | +1 (919) 786-8435

About Deep Lens

Deep Lens is a software company focused on a groundbreaking approach to faster recruitment of the best-suited cancer patients to clinical trials. By identifying patients at the time of diagnosis and combining lab, EMR, and genomic data, VIPER, Deep Lens’ integrated cloud platform, provides care teams with visibility and workflows to accelerate recruitment and compress study timelines to bring game-changing therapies to market sooner. Growing with sponsors, providers, and strategic partners, Deep Lens challenges the status quo so that patients can get the therapies they want and deserve. For more information, visit www.deeplens.ai.

MEDIA INQUIRIES: Jessica Yingling, Ph.D., President, Little Dog Communications
jessica@litldog.com | +1.858.344.8091

Secureworks Named a Leader in the IDC MarketScape: Worldwide Managed Security Services (MSS) 2020 Vendor Assessment

Report Highlights Secureworks’ Commitment to Software with Security at its Core

ATLANTA, Sept. 18, 2020 (GLOBE NEWSWIRE) — Secureworks® (NASDAQ:SCWX), a leader in software-driven security solutions, today announced it has been recognized as a Leader in the IDC MarketScape: Worldwide Managed Security Services (MSS) 2020 Vendor Assessment.1

The report also recognizes Secureworks’ multi-year strategy to build on in its expertise in security operations, by driving a collaborative, community-based approach to cybersecurity with software at its core.

This strategic shift was highlighted in the IDC MarketScape report, which stated, “A great deal of time and monetary investment has been put into Secureworks’ SaaS product Red Cloak™ Threat Detection and Response capabilities moving the company into a software provider shifting Secureworks into a product plus MSS service provider hybrid category over the past 24–36 months….Secureworks’ Threat Intelligence plays another differentiation in what the company provides to its customers.”

“As Secureworks transforms its business to provide more flexible, software-driven cybersecurity solutions, we’re proud to continue to be recognized as a Leader in the IDC MarketScape Worldwide Vendor Assessment,” said Michael R. Cote, Chief Executive Officer of Secureworks. “The industry is taking note of our innovative software transformation, and this report is a testament to our commitment to outpace and outmaneuver adversaries to protect customers worldwide.”

Since launch last year more than 200 customers have chosen Secureworks Red Cloak Threat Detection and Response cloud-native security application to transform their security operations, automate and simplify investigations, enable collaboration across security and IT functions in a single platform that sits at the heart of their security operations.

About Secureworks
Secureworks® (NASDAQ: SCWX), a global cybersecurity leader, enables our customers and partners to outpace and outmaneuver adversaries with more precision, so they can rapidly adapt and respond to market forces to meet their business needs. With a unique combination of cloud-native, SaaS security platform and intelligence-driven security solutions, informed by 20+ years of threat intelligence and research, no other security platform is grounded and informed with this much real-world experience.

www.secureworks.com

About IDC MarketScape
IDC MarketScape vendor analysis model is designed to provide an overview of the competitive fitness of ICT (information and communications technology) suppliers in a given market. The research methodology utilizes a rigorous scoring methodology based on both qualitative and quantitative criteria that results in a single graphical illustration of each vendor’s position within a given market. IDC MarketScape provides a clear framework in which the product and service offerings, capabilities and strategies, and current and future market success factors of IT and telecommunications vendors can be meaningfully compared. The framework also provides technology buyers with a 360-degree assessment of the strengths and weaknesses of current and prospective vendors.

1 IDC MarketScape: Worldwide Managed Security Services 2020 Vendor Assessment, by Martha Vazquez, September 2020, IDC # US46235320

Contact:
Ashley Vandiver
avandiver@secureworks.com
press@secureworks.com
+1 404-432-8657

Special Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934 and Section 27A of the Securities Act of 1933 and are based on Secureworks’ current expectations. In some cases, you can identify these statements by such forward-looking words as “anticipate,” “believe,” “confidence,” “could,” “estimate,” “expect,” “guidance,” “intend,” “may,” “plan,” “potential,” “outlook,” “should,” “will” and “would,” or similar words or expressions that refer to future events or outcomes. Because forward-looking statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, competitive uncertainties and general economic and business conditions in Secureworks’ markets as well as the other risks and uncertainties that are described in Secureworks’ periodic reports and other filings with the Securities and Exchange Commission, which are available for review through the Securities and Exchange Commission’s website at www.sec.gov. Any forward-looking statement speaks only as of the date as of which such statement is made, and, except as required by law, we undertake no obligation to update any forward-looking statement after the date as of which such statement was made, whether to reflect changes in circumstances or our expectations, the occurrence of unanticipated events, or otherwise. Any future product, service, feature, benefit or related specification referenced in this press release are for information purposes only and are not commitments to deliver any technology or enhancement.

Junshi Biosciences Receives Orphan Drug Designation from the U.S. FDA for Toripalimab for the Treatment of Soft Tissue Sarcoma

3rd Orphan Drug designation for Toripalimab

SHANGHAI, China, Sept. 17, 2020 (GLOBE NEWSWIRE) — Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the U.S. Food and Drug Administration (FDA) has recently granted Orphan Drug designation to Toripalimab for the treatment of soft tissue sarcoma. This is the third such designation granted to Toripalimab. The FDA has previously granted Orphan Drug designation for Toripalimab for the treatment of mucosal melanoma and nasopharyngeal carcinoma.

About Soft Tissue Sarcoma
Soft tissue sarcoma is a rare heterogeneous tumor with complex pathological types and obvious tumor heterogeneity. The current clinical treatment of soft tissue sarcoma mainly uses cytotoxic anti-tumor drugs, which have significant adverse reactions and poor tolerance. Alternative efficacious treatment with less side effects is urgently needed.

About Orphan Drug Designation
Orphan drugs refer to pharmaceutical products developed for the prevention, diagnosis, and treatment of rare diseases or conditions affecting fewer than 200,000 people in the U.S. at the time of designation. The orphan-drug designation granted by the FDA is beneficial for the continuous development of Toripalimab and the enjoyment of certain policy support in terms of registration and commercialization in the United States, including but not limited to: 1) tax credits for clinical trial costs; 2) waiver of application fees for new drugs; and 3) seven years of market exclusivity without being affected by patent. The designation will reduce the R&D investment on the new drug to a certain extent and accelerate the progress of clinical trials and market registration.

About Toripalimab
Toripalimab is an anti-PD-1 monoclonal antibody developed by Junshi Biosciences.  Toripalimab received its first approval for 2nd line treatment of metastatic melanoma on December 17, 2018 in China and was commercially launched in February 2019. So far, more than 30 clinical studies covering more than ten indications have been carried out in China, the United States and other countries.

In April 2020, the supplemental New Drug Application (“NDA”) of Toripalimab Injection for the treatment of new indications of recurrent/metastatic nasopharyngeal carcinoma after failure of second-line and above systemic treatment has been accepted by the NMPA. The supplemental NDA is the world’s first NDA of anti-PD-1 monoclonal antibody for the treatment of recurrent/metastatic nasopharyngeal carcinoma. In addition, JUPITER-02 study (NCT03581786), a Phase III clinical study of Toripalimab Injection combined with chemotherapy as a first-line treatment in patients with recurrent or metastatic nasopharyngeal carcinoma has completed the enrollment. In May 2020, the supplemental NDA of Toripalimab Injection for the treatment of new indications of locally advanced or metastatic urothelial carcinoma after systemic treatment has been accepted by the NMPA. The two supplemental NDAs were included in the process of priority review by the NMPA in July 2020. Toripalimab for the treatment of nasopharyngeal carcinoma was granted the Breakthrough Therapy designation by the FDA in September 2020.

In March 2020, Toripalimab in combination with axitinib in the treatment of mucosal melanoma was granted the orphan-drug designation by the FDA. In May 2020, Toripalimab was granted the orphan-drug designation by the FDA in the treatment of nasopharyngeal carcinoma.

About Junshi Biosciences
Founded in December 2012, Junshi Biosciences (HK: 1877; SH: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapeutics. The company has established a diversified R & D pipeline comprising 26 innovative drug candidates and 2 biosimilars, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurologic, and infectious diseases. Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for PD-1 monoclonal antibody in China and clinical trial application approval for anti PCSK9 monoclonal antibody from NMPA. The world’s first in human anti-BTLA antibody for solid tumors was officially approved for clinical trials by the FDA and NMPA. From this year onwards, Junshi Biosciences pooled its efforts with Chinese science institutions to co-develop JS016, China’s first neutralizing human monoclonal antibodies against SARS-Cov-2, that has entered clinical trial, part of our continuous innovation for disease control and prevention in China and beyond. We have about 2,000 employees in San Francisco and across Maryland in the United States, as well as Shanghai, Suzhou, Beijing, and Guangzhou, China. For more information, please visit: http://junshipharma.com.

Contact Information
IR Team:
Junshi Biosciences
info@junshipharma.com
+ 86 021-2250 0300

Solebury Trout
Bob Ai
bai@soleburytrout.com
+ 1 646.389.6658

PR Team:
Junshi Biosciences
Zhi Li
zhi_li@junshipharma.com
+ 86 021-6105 8800

Fresche Announces Expansion to its Automated Solutions that Accelerate IBM i (AS/400) Application Transformation to Modern Languages

Fresche broadens scope and adaptability of automated solutions to now transform RPG to PHP, producing high quality modern and scalable applications.

MONTREAL, Sept. 17, 2020 (GLOBE NEWSWIRE) — Fresche Solutions today introduced new capabilities with its automated solutions to accelerate application transformation of RPG applications into PHP, paving the way for faster digital innovation. Fresche’s automated solutions provide customers the ability to adopt agile modern systems and open languages by converting RPG to PHP or Java, and CA 2E (Synon) to Java. The addition of RPG to PHP gives companies running IBM i another option to enable competitive advantage while addressing inherent challenges with readily available skills, resources and difficult-to-maintain legacy applications. PHP is a leading open source choice of IBM i clients because it has a great, proven ecosystem and is an accessible language to create quality, maintainable code using RPG developers or existing PHP developers who have no experience on IBM i.

Most organizations are seeking better, faster ways to deliver powerful new digital experiences to their customers and employees. For companies that rely on legacy applications running on IBM’s Power Systems IBM i servers, this often requires piecing together capabilities from a mix of traditional and modern application architectures and technologies. As these organizations embrace open source, cloud, web and AI technologies and multi-threaded strategies, this landscape becomes more diverse and complex. Recognizing that legacy applications are not only core assets but that they contain competitive advantage and differentiation, Fresche keeps closing that divide—with skilled transformation experts, unique automated tooling, a proven methodology and flexible approaches to create the right strategy for each company.

Over the past few years, Fresche has made significant investment in developing the next generation of smart automated solutions that are offered in incremental delivery models and flexible financial models. These solutions provide a high level of automation and include services to ensure successful implementation. They reengineer the applications from monolithic to a modern code structure that is highly maintainable. In addition, a pre-conversion application assessment that provides a comprehensive forensic analysis of the entire system is produced by Fresche’s X‑Analysis Suite. This provides understanding of the applications and business rules as well as any opportunity for consolidation. The solutions also provide automated testing capabilities covering everything from the database to the UI. Combined, these solutions deliver modernized applications at lower cost and risk than rewriting or replacing while building on the investment in customized systems.

Nick Hampson, Senior Product Manager at Fresche, says that “Our transformation solutions are developed to be scalable and adaptable to support multiple languages. To date, our solutions currently transform the two biggest demands we’ve seen so far which are RPG to PHP or Java and Synon to Java, but we’re seeing a growing interest in other source and target languages. Companies recognize the value proposition that Power Systems IBM i brings, including its highly scalable and robust architecture, low TCO, reliability, security and integrated database. Our approach leverages their existing applications and skills to best meet the needs of the business. What differentiates Fresche from other modernization companies is three-fold. The adaptability of our automated solutions – they have evolved to the point where, with a small amount of enhancement, we can support a variety of target languages. In addition, our people are experts in transformation, which encompasses a deep understanding of both business and technology. And, because every client’s transformation journey is unique in everything from starting point to business goals to investment capability and delivery models, Fresche fits the solution to the needs – we don’t start with technology. To sum it up, every organization has different business challenges and technology is simply the enabler and means to solving those challenges.”

Marcel Sarrasin, Chief Product Officer at Fresche, points out that language conversion is a key part of digital transformation. “2020’s pandemic is forcing companies to adapt at a rapid pace. This is a real challenge for companies that rely on legacy systems and it underscores the importance of having an agile IT. We offer a unique incremental approach that delivers quick wins, demonstrates business value and aligns IT with business stakeholders. Our approach looks at many different options to transform or modernize your applications, including the user interface, database, business logic and web development solutions. Legacy systems are often competitive differentiators and leveraging them as the foundation for digital transformation is a smart way to innovate. Accelerated transformation is a precursor for clients who wish to take advantage of new technologies, agility and innovation. The addition of converting RPG to PHP gives companies another option to modernize their applications. Our IBM i clients are all at different stages in their transformation journey, and Fresche has solutions and services to help at any step.”

About Fresche Solutions

Fresche is the leading provider of application modernization and management solutions that enable digital transformation for companies that rely on IBM i systems. Through the power of automated tools and experienced professionals, Fresche delivers innovative solutions that bring our clients the best, boldest ways to modernize and better manage their business and IT.

Our professionals combine fresh thinking with technology and business expertise to help fuel transformation and growth for our clients and their customers. We do this by recycling our clients’ best IT assets to take advantage of digital solutions including web, mobile, cloud and AI – reducing time to market, lowering risk and cost, and making modernization affordable to every IBM i client on the planet.

With over 300 digitally connected colleagues around the world and an extensive network of business partners, Fresche collectively brings clients the best solutions to drive innovation and IT success.
For more information about our company, visit us on the web at www.freschesolutions.com

Twitter LinkedIn Facebook

For further details, please contact:

Christine McDowell, Fresche Solutions,
VP, Marketing
Cell: +1 514.220.1309
Email: Christine.mcdowell@freschesolutions.com
Marcel Sarrasin, Fresche Solutions,
Chief Product Officer
Tel: +1.250.655.1882
Cell: +1 250.857.5023
Email: marcel.sarrasin@freschesolutions.com

อนันตรา เวเคชั่น คลับ จัดเตรียมคอลเลคชั่นการเดินทางภายในประเทศ และโปรแกรมช่วยเหลือด้านการเงินแก่ท่านสมาชิกทั่วโลก

BANGKOK, Thailand, Sept. 16, 2020 (GLOBE NEWSWIRE) — กรุงเทพฯ ประเทศไทย อนันตรา เวเคชั่น คลับ ผู้นำโปรแกรมวันหยุดร่วมแถวหน้าของเอเชีย ซึ่งเปิดตัวในปี 2553 โดย ไมเนอร์ อินเตอร์เนชั่นแนล จำกัด (มหาชน) ได้ขยายตลาดภายในประเทศ และเปิดตัวโครงการใหม่เพื่อให้ความช่วยเหลือแก่ท่านสมาชิก (ท่านเจ้าของคะแนนคลับพอยท์) หลังจากที่เกิดเหตุการณ์แพร่ระบาดของโรคโควิด 19

anantara-vacation-club-wire-image

อนันตรา เวเคชั่น คลับ ผู้นำโปรแกรมวันหยุดร่วมแถวหน้าของเอเชีย ซึ่งเปิดตัวในปี 2553 โดย ไมเนอร์ อินเตอร์เนชั่นแนล จำกัด (มหาชน) ได้ขยายตลาดภายในประเทศ และเปิดตัวโครงการใหม่เพื่อให้ความช่วยเหลือแก่ท่านสมาชิก (ท่านเจ้าของคะแนนคลับพอยท์) หลังจากที่เกิดเหตุการณ์แพร่ระบาดของโรคโควิด 19

ทั้งนี้ ท่านเจ้าของคะแนนคลับพอยท์นอกจากสามารถเข้าพักที่คลับรีสอร์ทด้วยคะแนนคลับพอยท์เพียง 50% จนถึงวันที่ 22 ธันวาคม 2563 แล้ว ยังจะได้รับส่วนลดสำหรับการเข้าพักที่คลับเอสเคป ทั้งรีสอร์ทที่มีอยู่ปัจจุบันและที่เปิดตัวใหม่ อาทิ ประเทศไทย (อนันตรา หัวหิน รีสอร์ท, อวานี พลัส หัวหิน รีสอร์ท และ อวานี พัทยา รีอสอร์ท แอนด์ สปา) ประเทศมาเลเซีย (อนันตรา เดซารูโคสต์ รีสอร์ทแอนด์วิลล่าส์ และ ดอร์เซต กัวลาลัมเปอร์) และประเทศออสเตรเลีย (อวานี บรอดบีช เรสซิเดนซ์, โอ๊คส์ เมลเบิร์น ออน มาร์เก็ต โฮเท็ล, แรพ ออน เซาธ์แบงค์ และโอ๊คส์ ซิดนีย์ โกลด์สบรูค อพาร์ทเมนท์)

อนันตรา เวเคชั่น คลับได้เป็นพันธมิตรกับ ทราวิลี่  โปรแกรมการเดินทางที่พร้อมนำเสนอตัวเลือกการเดินทางที่หลากหลาย ด้วยจุดหมายปลายทางแห่งใหม่ภายในประเทศ/เขตปกครองพิเศษ อาทิ ฮ่องกง ฟิลิปปินส์ เกาหลีใต้ ไต้หวัน และญี่ปุ่น อีกทั้งยังมีโปรแกรม ไชน่า คอลเลคชั่น โดย อนันตรา เวเคชั่น คลับ สำหรับท่านเจ้าของคะแนนคลับพอยท์ที่พำนักอยู่ในประเทศจีนให้ได้เพลิดเพลินไปกับจุดหมายปลายทางใหม่ๆ มากกว่า 15 แห่งในหลากหลายภูมิภาค

“สืบเนื่องจากผลกระทบของเหตุการณ์แพร่ระบาดของโรคโควิด 19 ที่ส่งผลทั่วโลก เราได้ตระหนักถึงความสำคัญในการรักษามาตรฐานในการปรับตัวและลงมือปฏิบัติอย่างรวดเร็ว เนื่องด้วยยังคงมีข้อจำกัดจำนวนมากในการเดินทางระหว่างประเทศ เราจึงต้องตอบสนองความต้องการที่เพิ่มขึ้นสำหรับตัวเลือกการเดินทางภายในประเทศ เพื่อเป็นการอำนวยความสะดวกให้แก่ท่านเจ้าของคะแนนคลับพอยท์ของเราที่ไม่สามารถเดินทางไปต่างประเทศได้ในขณะนี้” เมาริซิโอ บิสซิคกี้ (Maurizio Bisicky) ประธานเจ้าหน้าที่บริหารฝ่ายปฏิบัติการ อนันตรา เวเคชั่น คลับ กล่าว

“การขยายอายุคะแนนคลับพอยท์ออกไปเป็นเวลา 12 เดือน และการยกเว้นค่าธรรมเนียมการเปลี่ยนแปลงหรือยกเลิกรายการสำรองห้องพักนั้น เป็นสิ่งที่ตอบโจทย์ในสถานการณ์ปัจจุบัน ทั้งนี้ก็เพื่อตอบสนองต่อความจำเป็นที่เกิดขึ้น เราทำงานร่วมกับพันธมิตรทั่วโลกและได้เปิดตัวคอลเลคชั่นการเดินทางในหลายประเทศเพิ่มเติม โดยขณะนี้กำลังอยู่ในระหว่างการพัฒนาสำหรับมาร์เก็ตอื่นๆ”

นอกจากการเพิ่มจุดหมายปลายทางใหม่ภายในประเทศแล้ว อนันตรา เวเคชั่น คลับ ยังได้เปิดตัวโปรแกรมเพื่อสนับสนุนและช่วยเหลือท่านเจ้าของคะแนนคลับพอยท์ที่อาจเผชิญความยากลำบากทางด้านการเงิน โดยโปรแกรมดังกล่าวจะอำนวยความสะดวกด้วยตัวเลือกการชำระค่าธรรมเนียมรายปีด้วยคะแนนคลับพอยท์ ตัวเลือกในการขยายอายุการใช้งานของคะแนนคลับพอยท์ปี 2564 และการปรับโครงสร้างใหม่สำหรับแผนการชำระเงิน ทั้งนี้ทางคลับยังประสานงานกับท่านเจ้าของคะแนนคลับพอยท์เป็นรายบุคคล เพื่อปรับปรุงวิธีการแก้ไขปัญหาต่างๆตามความต้องการของแต่ละบุคคลด้วย

ขณะนี้ คลับรีสอร์ทในประเทศไทยได้เปิดให้บริการสำหรับนักเดินทางภายในประเทศแล้ว และอนันตรา เวเคชั่น คลับ ณ อวานี เซมินยัค บาหลี ซึ่งเพิ่งได้รับการเสนอชื่อให้เป็น ‘2020 Traveler’s Choice Winner’ โดย Tripadvisor ก็มีกำหนดจะเปิดให้บริการอีกครั้งทันทีที่ข้อจำกัดการเดินทางเริ่มผ่อนคลายลง

เกี่ยวกับอนันตรา เวเคชั่น คลับ 

อนันตรา เวเคชั่น คลับ เจ้าของโปรแกรมวันหยุดร่วมแถวหน้าของเอเชีย เปิดตัวในปี 2553 โดย ไมเนอร์ อินเตอร์เนชั่นแนล จำกัด (มหาชน) ผู้เป็นเจ้าของโรงแรมในเครือ ไมเนอร์ โฮเทลส์ นำเสนอคลับรีสอร์ทอันหรูหราถึง 8 แห่ง ทั้งในประเทศไทย อินโดนีเซีย และนิวซีแลนด์ เปิดโอกาสให้ท่านเจ้าของคะแนนคลับพอยท์และผู้เข้าพัก ได้ค้นพบประสบการณ์สุดประทับใจ ณ สถานที่ท่องเที่ยวชั้นนำต่างๆ  โดยท่านเจ้าของคะแนนคลับพอยท์จะได้รับความยืดหยุ่นในการเดินทางยิ่งขึ้นด้วยโปรแกรมคลับเอสเคป และโกลบอล ทราเวลเลอร์ ที่ให้ท่านเจ้าของคะแนนคลับพอยท์สามารถเข้าถึงรีสอร์ทและโรงแรมพันธมิตรหลายร้อยแห่งทั่วโลก

สำหรับข้อมูลเพิ่มเติม กรุณาเยี่ยมชม www.anantaravacationclub.com หรือติดตามบล็อกของ อนันตรา เวเคชั่น คลับ หรือ ติดตามผ่านบล็อกของเรา หรือสื่อสังคมออนไลน์ บน Facebook, Twitter, Instagram และ Weibo

เกี่ยวกับ ไมเนอร์ โฮเทลส์

ไมเนอร์ โฮเทลส์ เป็นเจ้าของธุรกิจโรงแรมระดับอินเตอร์เนชั่นแนล ทั้งในรูปแบบการเป็นเจ้าของ ผู้ดำเนินการ และผู้ลงทุน โดยมีโรงแรมทั้งสิ้น 549 แห่ง ภายใต้แบรนด์ อนันตรา, อวานี, โอ๊คส์, ทิโวลี, เอ็นเอช คอลเลคชั่น, เอ็นเอช, นาว, เอเลวาน่า, แมริออท, โฟร์ซีซั่นส์, เซ็นต์ รีจิส, เรดิสัน บลู และที่พักภายใต้แบรนด์ ไมเนอร์ อินเตอร์เนชั่นแนล ในอีก 55 ประเทศทั่วภูมิภาคเอเชียแปซิฟิก, ตะวันออกกลาง, แอฟริกา,มหาสมุทรอินเดีย, ยุโรป อเมริกาใต้ และอเมริกาเหนือ ไมเนอร์ โฮเทลส์ มีแผนในการขับเคลื่อนไปข้างหน้าและการสร้างการเติบโตให้กับแบรนด์ที่มีอยู่ ผ่านการเข้าควบรวมกิจการในตลาดใหม่ๆ ที่มีโอกาสในการเติบโต  ไมเนอร์ โฮเทลส์ ยังได้ดำเนินวิสัยทัศน์ ในการสร้างโลกที่เต็มไปด้วยพลังและเชื่อมโยงกันมากขึ้น หากต้องการทราบข้อมูลเพิ่มเติม โปรดเข้าไปที่ www.minorhotels.com

สำหรับสื่อมวลชน โปรดติดต่อ

เอเชียตะวันออกเฉียงใต้

Andrew Schiff
T: +66 (0) 2365 7500 ext. 5806
E: aschiff@anantaraclub.com

ประเทศจีน

Cathy Shao
T: +86 21 2308 7726
E: cshao@anantaraclub.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/869195af-6bdd-431c-a47d-419fae74e75e